Acute Dyspnea From Treatment of AL Amyloidisis With Bortezomib
Authors:
- Abhimanyu GhoseAGAbhimanyu Ghose
- Zeeshan TariqZTZeeshan Tariq
- Asma TajATAsma Taj
- Rekha ChaudharyRCRekha Chaudhary
- 1 July 2011
- journal article
- case report
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 18 (4) , e123-e125
Abstract
Bortezomib with or without dexamethasone has been reported to be very effective and well tolerated in the treatment of AL amyloidosis. Commonly reported adverse effects are fatigue, nausea, vomiting, diarrhea, constipation, postural hypotension from autonomic neuropathy, peripheral neuropathy, thrombocytopenia and anemia. Dyspnea has been rarely reported as an adverse effect of bortezomib therapy in AL amyloidosis. We are reporting three case reports of patients suffering from AL amyloidodis, who had new onset acute dyspnea secondary to bortezomib treatment that required drug discontinuation. There might be some correlation between the AL amyloidosis disease and bortezomib associated dyspnea, but the pathophysiology is poorly understood.Keywords
This publication has 3 references indexed in Scilit:
- Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation studyBlood, 2009
- Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal diseaseHaematologica, 2008
- Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasoneHaematologica, 2007